Derek Ruff, UC San Diego Health (IMAGE)

University of California - San Diego

Derek Ruff, UC San Diego Health

Caption

Derek Ruff enrolled in a phase I clinical trial at Moores Cancer Center at UC San Diego Health of a new iPSC-derived natural killer cell cancer immunotherapy developed by Fate Therapeutics that received U.S. Food and Drug Administration approval in November 2018.

Credit

UC San Diego Health

Usage Restrictions

Use photo credit as indicated

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.